New Combination of Triamcinolone, 5-Fluorouracil, and Pulsed-Dye Laser for Treatment of Keloid and Hypertrophic Scars
- 1 July 2006
- journal article
- research article
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 32 (7) , 907-915
- https://doi.org/10.1111/j.1524-4725.2006.32195.x
Abstract
Keloids and hypertrophic scars are benign growths of dermal collagen that usually cause major physical, psychological, and cosmetic problems. In this 12-week single-blinded clinical trial, 69 patients were randomly assigned into three study groups. In Group 1, intralesional triamcinolone acetonide (TAC, 10 mg/mL) was injected at weekly intervals for a total of 8 weeks. In Group 2 [TAC+5-fluorouracil (5-FU)], 0.1 mL of 40 mg/mL TAC was added to 0.9 mL of 5-FU (50 mg/mL). This combination was injected weekly for 8 weeks. In Group 3, in addition to weekly TAC+5-FU injection for 8 weeks, lesions were irradiated by 585-nm flashlamp-pumped pulsed-dye laser (PDL, 5-7.5 J/cm2) at the 1st, 4th, and 8th weeks. Lesions were assessed for erythema, pruritus, pliability, height, length, and width. Sixty patients completed the study. At the 8- and 12-week follow-up visits, all groups showed an acceptable improvement in nearly all measures, but in comparison between groups, these were statistically more significant in the TAC+5-FU and TAC+5-FU+PDL groups (p<.05 for all). At the end of the study, the erythema score was significantly lower, and itch reduction was statistically higher in the TAC+5-FU+PDL group (p<.05 for both). Good to excellent improvements (>50% improvement) were reported by the patients as follows: 20% in Group 1, 55% in Group 2, and 75% in Group 3, all of which were significantly different (p<.05). Good to excellent responses were reported by the blinded observer as follows: 15% in Group 1, 40% in Group 2, and 70% in Group 3. Their differences were statistically significant (p<.05). Atrophy and telangiectasia were seen in 37% of patients in TAC group. Overall efficacy of TAC+5-FU was comparable with TAC+5-FU+PDL, but the TAC+5-FU+PDL combination was more acceptable by the patients and produced better results. Its effect on lightening of the lesion was promising. The TAC+5-FU+PDL combination seems to be the best approach for treatment of keloid and hypertrophic scars.Keywords
This publication has 26 references indexed in Scilit:
- Intralesional 5-fluorouracil in the treatment of keloids: An open clinical and histopathologic studyJournal of the American Academy of Dermatology, 2005
- Suppressed TGF-?1 expression is correlated with up-regulation of matrix metalloproteinase-13 in keloid regression after flashlamp pulsed-dye laser treatmentLasers in Surgery and Medicine, 2005
- The Use of Pulsed Dye Laser for the Prevention and Treatment of Hypertrophic Scars in Chinese PersonsDermatologic Surgery, 2004
- Medical and surgical therapies for keloidsDermatologic Therapy, 2004
- 5-Fluorouracil Blocks Transforming Growth Factor-β–Induced α2 Type I Collagen Gene (COL1A2) Expression in Human Fibroblasts via c-Jun NH2-Terminal Kinase/Activator Protein-1 ActivationMolecular Pharmacology, 2003
- Treatment Response of Keloidal and Hypertrophic Sternotomy ScarsArchives of Dermatology, 2002
- Energy density and numbers of treatment affect response of keloidal and hypertrophic sternotomy scars to the 585-nm flashlamp-pumped pulsed-dye laserJournal of the American Academy of Dermatology, 2001
- The molecular basis of keloid and hypertrophic scar formationMolecular Medicine Today, 1998
- An alternative molecular mechanism of action of 5-fluorouracil, a potent anticancer drugBiochemical Pharmacology, 1997
- Selection of Therapeutic Agents for Intraocular Proliferative DiseaseArchives of Ophthalmology (1950), 1984